Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lytic Cycle of Bacteriophages01:30

Lytic Cycle of Bacteriophages

71.5K
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the...
71.5K
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

511
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
511
Lysogenic Cycle of Bacteriophages00:43

Lysogenic Cycle of Bacteriophages

62.9K
In contrast to the lytic cycle, phages infecting bacteria via the lysogenic cycle do not immediately kill their host cell. Instead, they combine their genome with the host genome, allowing the bacteria to replicate the phage DNA along with the bacterial genome. The incorporated copy of the phage genome is called the prophage. Some prophages can re-activate and enter the lytic cycle. This often occurs in response to a perturbation, such as DNA damage, but can also transpire in the absence of...
62.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

248
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
248
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

264
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
264
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

219
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
219

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

3-D pathological analysis of varicose microvascular vessels in sessile serrated lesions seen on endoscopy.

Endoscopy·2026
Same author

Age-dependent vascular and neurological characteristics of CADASIL are recapitulated in Notch3 mutant zebrafish, implicating a role for type IV collagen in disease progression.

Acta neuropathologica communications·2026
Same author

Programming systemic and mucosal immunity through co-adjuvant-based prime-boost vaccination.

Current opinion in virology·2026
Same author

Increased Gut Microbiota Diversity in Patients With Retinitis Pigmentosa and Implications for Disease Phenotypes and Progression.

Investigative ophthalmology & visual science·2026
Same author

Development of gastric mucosa-associated microbiota in autoimmune gastritis with neuroendocrine tumors.

Journal of gastroenterology·2025
Same author

An adjuvant database for preclinical evaluation of vaccines and immunotherapeutics.

Cell chemical biology·2025

Related Experiment Video

Updated: Aug 21, 2025

Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice
08:46

Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice

Published on: January 26, 2024

1.8K

Phage therapy for Clostridioides difficile infection.

Kosuke Fujimoto1,2, Satoshi Uematsu1,2

  • 1Department of Immunology and Genomics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

Frontiers in Immunology
|November 17, 2022
PubMed
Summary
This summary is machine-generated.

Clostridioides difficile infections are a growing concern, prompting research into new treatments. This review highlights phage therapy as a promising alternative to fecal microbiota transplantation for C. difficile.

Keywords:
Clostridioides difficilebacteriophagecell wall-binding domainendolysinenzyme active domainmetagenome

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.2K
Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
11:20

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Published on: May 12, 2020

6.6K

Related Experiment Videos

Last Updated: Aug 21, 2025

Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice
08:46

Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice

Published on: January 26, 2024

1.8K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.2K
Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
11:20

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Published on: May 12, 2020

6.6K

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Genomics

Background:

  • Clostridioides difficile (C. difficile) is a common cause of healthcare-associated infections, particularly nosocomial diarrhea after antibiotic use.
  • Emerging highly virulent strains and antimicrobial resistance contribute to treatment failures and relapses of C. difficile infections.
  • Fecal microbiota transplantation (FMT) is effective for recurrent C. difficile but carries safety concerns, including reported deaths from antibiotic-resistant infections post-transplant.

Purpose of the Study:

  • To review the significance of phage therapy as a treatment for C. difficile infections.
  • To introduce a novel, next-generation phage therapy approach for C. difficile.

Main Methods:

  • Literature review of C. difficile pathogenesis, treatment challenges, and phage therapy applications.
  • Description of a novel phage therapy strategy developed utilizing metagenomic data analysis.

Main Results:

  • Phage therapy presents a viable, targeted approach to combatting C. difficile.
  • Next-generation phage therapy, informed by metagenomics, offers a potentially safer and more effective alternative.

Conclusions:

  • There is an urgent need for effective C. difficile-specific treatments beyond antibiotics and FMT.
  • Next-generation phage therapy holds significant promise for managing C. difficile infections and addressing antimicrobial resistance.